DataSheet_1_Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.docx

Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.

多种因素（包括疫苗平台与既往接种史）可影响疫苗应答效果。本研究针对巴西874名医护人员，对比了接种CoronaVac（Sinovac）与ChAdOx1-S（AstraZeneca-Oxford）疫苗后的抗体应答情况。由于受试者在接种前0至6个月曾被随机分配接种卡介苗（BCG）或安慰剂，这是「降低医护人员新冠感染影响的卡介苗接种（BRACE）」试验的一部分，因此本研究同时探讨了近期接种卡介苗对上述两款新冠疫苗抗体应答的影响。在接种每款疫苗的第二剂后28天，ChAdOx1-S诱导的抗刺突IgG抗体应答强度高于CoronaVac接种组。近期接种卡介苗并未对ChAdOx1-S或CoronaVac的IgG抗体应答产生影响。